Theravance Biopharma Shareholders Approve Merger with Zymeworks

Key Facts

1Theravance Biopharma shareholders have voted in favor of the merger agreement with Zymeworks.

In a move reflecting the accelerating pace of consolidation within the biotechnology sector, Theravance Biopharma shareholders have officially voted in favor of the proposed merger with Zymeworks. According to reports, this approval marks a critical milestone in the process of combining the two companies' operations, aiming to unify resources and research pipelines. The vote follows a previous merger agreement announcement as both entities seek to enhance their operational scale.

This development reduces deal uncertainty for these mid-cap biotech entities within the broader market context. Per market data, TBPH shares closed at $17.04, while ZYME shares stood at $27.48 (close of September 17, 2026). These price levels reflect the market's positioning ahead of the formal shareholder confirmation regarding the business combination.

Investors should watch for the final closing steps of the merger, with TBPH at $17.04 and ZYME at $27.48 as of the September 17, 2026 close. Given the absence of immediate sector-specific catalysts in the upcoming economic calendar, focus will remain on the timeline for full legal and operational integration between the two firms.